Idine Mousavi

Idine Mousavi

Auto-generated profile, based on publicly available information

Idine Mousavi

Department of Medicine, Baylor College of Medicine, Houston, TX, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2024 in European Journal of Preventive Cardiology
Verified
Journal Article
Closed access
PDF file
IMIdine Mousavi
Idine Mousavi
JSJohn Suffredini
John Suffredini
SPSalim S Virani MD, PhD
Salim S Virani MD, PhD
CBChristie M. Ballantyne
Christie M. Ballantyne
EMErin D Michos
Erin D Michos
XJXiaoming Jia
Xiaoming Jia
Recent trends indicate a concerning increase in early-onset atherosclerotic cardiovascular disease (ASCVD) among younger individuals (men aged <55 years women aged <65 years). These findings highlight the pathobiology of ASCVD as a disease process that begins early in life and underscores the need for more tailored screening methods and preventive strategies. Increasing attention has been placed on the growing burden of traditional cardiometabolic risk factors in young individuals while also recognizing unique factors that mediate risk of pre-mature atherosclerosis in this demographic such as substance use, socioeconomic disparities, adverse pregnancy outcomes, and chronic inflammatory states that contribute to the increasing incidence of early ASCVD. Additionally, mounting evidence has pointed out significant disparities in the diagnosis and management of early ASCVD and cardiovascular outcomes based on sex and race. Moving towards a more personalized approach, emerging data and technological developments using diverse tools such as polygenic risk scores and coronary artery calcium scans have shown potential in earlier detection of ASCVD risk. Thus, we review current evidence on causal risk factors that drive the increase in early ASCVD and highlight emerging tools to improve ASCVD risk assessment in young individuals.

6 August 2024 in American Journal of Preventive Cardiology
Verified
Journal Article
Open access
IMIdine Mousavi
Idine Mousavi
VNVijay Nambi
Vijay Nambi
LALayla A. Abushamat
Layla A. Abushamat
SASadeer G. Al-Kindi
Sadeer G. Al-Kindi
MSMichael D. Shapiro
Michael D. Shapiro
AMAbdul Mannan Khan Minhas
Abdul Mannan Khan Minhas
• Bempedoic acid has been shown to reduce major adverse cardiovascular outcomes in patients unable to take statins due to statin-associated side effects. • Analysis of CLEAR Outcomes trial data reveals possible differences in baseline characteristics between the primary and secondary prevention subgroups. • Further research is needed to optimize use of bempedoic acid and clarify its impact on cardiovascular outcomes in diverse patient populations.